Increased epidermal growth factor receptor (EGFR) gene copy numbers and mutations
predict sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer (NSCLC) …

Purpose: The epidermal growth factor receptor (EGFR) is frequently overexpressed in non–
small-cell lung carcinoma (NSCLC), and EGFR inhibitors are promising new therapeutic …

Background: Survival benefit of non-small-cell lung cancer (NSCLC) patients treated with
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors is predicted by high …

Next to EGFR mutation, EGFR gene copy number evaluated by fluorescence in situ
hybridization (FISH) emerged as a potential predictive marker for sensitivity to EGFR …

Background: Gefitinib is a selective inhibitor of the epidermal growth factor (EGFR) tyrosine
kinase, which is overexpressed in many cancers, including non–small-cell lung cancer …

To evaluate the epidermal growth factor receptor (EGFR) protein expression and increased
copy number as predictors of clinical outcome in patients with non-small-cell lung cancer …

Background Very recent studies have suggested that EGFR gene copy number and
expression obtained by fluorescence in situ hybridization (FISH) and immunohistochemistry …

Background: Biological markers for optimal selection of patient to epidermal growth factor
receptor (EGFR)-targeted therapies are not established in advanced non-small-cell lung …

To evaluate the association of epidermal growth factor receptor (EGFR) gene copy number
with EGFR and k-ras mutation status and tyrosine kinase inhibitor (TKI) sensitivity in non …

Background EGFR gene mutation is independently associated with a favorable response in
non–small-cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor …